Dataset of ultralow temperature refrigeration for COVID 19 vaccine distribution solution

Jian Sun; Mingkan Zhang; Anthony Gehl; Brian Fricke; Kashif Nawaz; Kyle Gluesenkamp; Bo Shen; Jeff Munk; Joe Hagerman; Melissa Lapsa; Nader Awwad; Chris Recipe; Doug Auyer; David Brisson

doi:10.1038/s41597-022-01167-y

Dataset of ultralow temperature refrigeration for COVID 19 vaccine distribution solution

Jian Sun, Mingkan Zhang, Anthony Gehl, Brian Fricke, Kashif Nawaz, Kyle Gluesenkamp, Bo Shen, Jeff Munk, Joe Hagerman, Melissa Lapsa, Nader Awwad, Chris Recipe, Doug Auyer, David Brisson

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Most COVID-19 vaccines require temperature control for transportation and storage. Two types of vaccine have been developed by manufacturers (Pfizer and Moderna). Both vaccines are based on mRNA and lipid nanoparticles requiring low temperature storage. The Pfizer vaccine requires ultra-low temperature storage (−80 °C to −60 °C), while the Moderna vaccine requires −30 °C storage. However, the last stage of distribution is quite challenging, especially for rural or suburban areas, where local towns, pharmacy chains and hospitals may not have the infrastructure required to store the vaccine at the required temperature. In addition, there is limited data available to address ancillary challenges of the distribution framework for both transportation and storage stages, including safety concerns due to human exposure to large amounts of CO₂ from dry-ice sublimation, issues due to the pressure increase caused by dry-ice sublimation, and the potential issue caused by non-uniform cryogenic temperatures. As such, there is a need for test dataset to assist the development of a quick, effective, secure, and safe solution to mitigate the challenges faced by vaccine distribution logistics.

Original language	English
Article number	67
Journal	Scientific Data
Volume	9
Issue number	1
DOIs	https://doi.org/10.1038/s41597-022-01167-y
State	Published - Dec 2022

Funding

Funding for this research was provided by the US Department of Energy, Office of Energy Efficiency and Renewable Energy, Building Technology Office. The authors would like to thank Erika Gupta, Samuel Petty, and Ed Vineyard, Program Managers of Building Technologies Office, for their support of this work. The authors would like to thank the support from Gerald Barth, Margret Smith, Brandy Milun of ORNL to support the preparation of the lab test 2. The authors would like to thank leadership team’s support from both ORNL ESTD (Xin Sun, Lonnie Love, Marti Head, Ron Ott, Richard Raines, Robert Wagner, Yarom Polsky) and Carrier Global Corporation (Bruce Hoopes, Yu Chen, Stella Oggianu, James Fan). This manuscript has been authored in part by UT-Battelle, LLC, under contract DE-AC05-00OR22725 with the US Department of Energy (DOE). The US government retains and the publisher, by accepting the article for publication, acknowledges that the US government retains a nonexclusive, paid-up, irrevocable, worldwide license to publish or reproduce the published form of this manuscript, or allow others to do so, for US government purposes. DOE will provide public access to these results of federally sponsored research in accordance with the DOE Public Access Plan (http://energy.gov/downloads/doe-public-access-plan). Funding for this research was provided by the US Department of Energy, Office of Energy Efficiency and Renewable Energy, Building Technology Office. The authors would like to thank Erika Gupta, Samuel Petty, and Ed Vineyard, Program Managers of Building Technologies Office, for their support of this work. The authors would like to thank the support from Gerald Barth, Margret Smith, Brandy Milun of ORNL to support the preparation of the lab test 2. The authors would like to thank leadership team’s support from both ORNL ESTD (Xin Sun, Lonnie Love, Marti Head, Ron Ott, Richard Raines, Robert Wagner, Yarom Polsky) and Carrier Global Corporation (Bruce Hoopes, Yu Chen, Stella Oggianu, James Fan). This manuscript has been authored in part by UT-Battelle, LLC, under contract DE-AC05-00OR22725 with the US Department of Energy (DOE). The US government retains and the publisher, by accepting the article for publication, acknowledges that the US government retains a nonexclusive, paid-up, irrevocable, worldwide license to publish or reproduce the published form of this manuscript, or allow others to do so, for US government purposes. DOE will provide public access to these results of federally sponsored research in accordance with the DOE Public Access Plan ( http://energy.gov/downloads/doe-public-access-plan ).

Funders	Funder number
Carrier Global Corporation
DOE Public Access Plan
Oak Ridge National Laboratory
Office of Energy Efficiency and Renewable Energy, Building Technology Office
U.S. Department of Energy
Oak Ridge National Laboratory	DE-AC05-00OR22725

Access to Document

10.1038/s41597-022-01167-y

Cite this

@article{28bd9015a7554a9fabf57c4714db3004,

title = "Dataset of ultralow temperature refrigeration for COVID 19 vaccine distribution solution",

abstract = "Most COVID-19 vaccines require temperature control for transportation and storage. Two types of vaccine have been developed by manufacturers (Pfizer and Moderna). Both vaccines are based on mRNA and lipid nanoparticles requiring low temperature storage. The Pfizer vaccine requires ultra-low temperature storage (−80 °C to −60 °C), while the Moderna vaccine requires −30 °C storage. However, the last stage of distribution is quite challenging, especially for rural or suburban areas, where local towns, pharmacy chains and hospitals may not have the infrastructure required to store the vaccine at the required temperature. In addition, there is limited data available to address ancillary challenges of the distribution framework for both transportation and storage stages, including safety concerns due to human exposure to large amounts of CO2 from dry-ice sublimation, issues due to the pressure increase caused by dry-ice sublimation, and the potential issue caused by non-uniform cryogenic temperatures. As such, there is a need for test dataset to assist the development of a quick, effective, secure, and safe solution to mitigate the challenges faced by vaccine distribution logistics.",

author = "Jian Sun and Mingkan Zhang and Anthony Gehl and Brian Fricke and Kashif Nawaz and Kyle Gluesenkamp and Bo Shen and Jeff Munk and Joe Hagerman and Melissa Lapsa and Nader Awwad and Chris Recipe and Doug Auyer and David Brisson",

note = "Publisher Copyright: {\textcopyright} 2022, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.",

year = "2022",

month = dec,

doi = "10.1038/s41597-022-01167-y",

language = "English",

volume = "9",

journal = "Scientific Data",

issn = "2052-4463",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Dataset of ultralow temperature refrigeration for COVID 19 vaccine distribution solution

AU - Sun, Jian

AU - Zhang, Mingkan

AU - Gehl, Anthony

AU - Fricke, Brian

AU - Nawaz, Kashif

AU - Gluesenkamp, Kyle

AU - Shen, Bo

AU - Munk, Jeff

AU - Hagerman, Joe

AU - Lapsa, Melissa

AU - Awwad, Nader

AU - Recipe, Chris

AU - Auyer, Doug

AU - Brisson, David

PY - 2022/12

Y1 - 2022/12

N2 - Most COVID-19 vaccines require temperature control for transportation and storage. Two types of vaccine have been developed by manufacturers (Pfizer and Moderna). Both vaccines are based on mRNA and lipid nanoparticles requiring low temperature storage. The Pfizer vaccine requires ultra-low temperature storage (−80 °C to −60 °C), while the Moderna vaccine requires −30 °C storage. However, the last stage of distribution is quite challenging, especially for rural or suburban areas, where local towns, pharmacy chains and hospitals may not have the infrastructure required to store the vaccine at the required temperature. In addition, there is limited data available to address ancillary challenges of the distribution framework for both transportation and storage stages, including safety concerns due to human exposure to large amounts of CO2 from dry-ice sublimation, issues due to the pressure increase caused by dry-ice sublimation, and the potential issue caused by non-uniform cryogenic temperatures. As such, there is a need for test dataset to assist the development of a quick, effective, secure, and safe solution to mitigate the challenges faced by vaccine distribution logistics.

AB - Most COVID-19 vaccines require temperature control for transportation and storage. Two types of vaccine have been developed by manufacturers (Pfizer and Moderna). Both vaccines are based on mRNA and lipid nanoparticles requiring low temperature storage. The Pfizer vaccine requires ultra-low temperature storage (−80 °C to −60 °C), while the Moderna vaccine requires −30 °C storage. However, the last stage of distribution is quite challenging, especially for rural or suburban areas, where local towns, pharmacy chains and hospitals may not have the infrastructure required to store the vaccine at the required temperature. In addition, there is limited data available to address ancillary challenges of the distribution framework for both transportation and storage stages, including safety concerns due to human exposure to large amounts of CO2 from dry-ice sublimation, issues due to the pressure increase caused by dry-ice sublimation, and the potential issue caused by non-uniform cryogenic temperatures. As such, there is a need for test dataset to assist the development of a quick, effective, secure, and safe solution to mitigate the challenges faced by vaccine distribution logistics.

UR - http://www.scopus.com/inward/record.url?scp=85125614647&partnerID=8YFLogxK

U2 - 10.1038/s41597-022-01167-y

DO - 10.1038/s41597-022-01167-y

M3 - Article

C2 - 35236859

AN - SCOPUS:85125614647

SN - 2052-4463

VL - 9

JO - Scientific Data

JF - Scientific Data

IS - 1

M1 - 67

ER -

Dataset of ultralow temperature refrigeration for COVID 19 vaccine distribution solution

Abstract

Funding

Access to Document

Other files and links

Fingerprint

Cite this